Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have been given a consensus rating of “Buy” by the ten analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $65.44.

Several brokerages recently weighed in on VERA. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Wedbush boosted their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the company a “neutral” rating in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $29.52 on Friday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics has a twelve month low of $25.99 and a twelve month high of $51.61. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -11.31 and a beta of 1.11. The company’s fifty day moving average is $37.82 and its 200 day moving average is $40.72.

Insider Activity

In related news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the sale, the chief executive officer now owns 85,942 shares in the company, valued at $3,701,521.94. This represents a 16.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 52,500 shares of company stock worth $2,305,625. Company insiders own 21.70% of the company’s stock.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Avoro Capital Advisors LLC grew its position in Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after purchasing an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Vera Therapeutics by 11.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock worth $185,107,000 after buying an additional 437,940 shares during the period. FMR LLC boosted its holdings in Vera Therapeutics by 9.6% in the 4th quarter. FMR LLC now owns 3,053,126 shares of the company’s stock worth $129,117,000 after buying an additional 267,842 shares during the period. Vanguard Group Inc. lifted its stake in Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after purchasing an additional 369,387 shares in the last quarter. Finally, Holocene Advisors LP lifted its stake in Vera Therapeutics by 8.8% in the 3rd quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock worth $86,390,000 after purchasing an additional 158,451 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.